Home › Companies › Ultragenyx Pharmaceutical Inc. › 2025-2026
Compiled from SEC Form N-PX filings and Ultragenyx Pharmaceutical Inc.’s Form 8-K, filed 2026-05-18 (Item 5.07 on EDGAR). Page generated 04 October 2026.
Explore Ultragenyx Pharmaceutical Inc. in the interactive database Compare manager voting policies
These tallies are Ultragenyx Pharmaceutical Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2026-05-18 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Outcome |
|---|---|---|---|---|---|---|
| Elect Director: Emil D. Kakkis, M.D., Ph.D. | 72,517,613 | -- | -- | 1,056,885 | 11,211,890 | Majority: yes |
| Elect Director: Shehnaaz Suliman, M.D. | 65,801,638 | -- | -- | 7,772,860 | 11,211,890 | Majority: yes |
| Elect Director: Daniel G. Welch | 66,301,426 | -- | -- | 7,273,072 | 11,211,890 | Majority: yes |
| Proposal 2: Approval of the Third A&R 2023 Plan At the Annual Meeting, the Company's stockholders approved the Third A&R 2023 Plan. The votes on Proposal 2 were as follows: | 50,659,150 | 22,888,600 | 26,748 | -- | 11,211,890 | Majority: yes |
| Proposal 3: Ratification of Selection of Independent Registered Accounting Firm At the Annual Meeting, the Company's stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal yea | 84,551,399 | 221,802 | 13,187 | -- | -- | Majority: yes |
| Proposal 4: Advisory (Non-Binding) Vote to Approve Executive Compensation At the Annual Meeting, the Company's stockholders voted, on an advisory basis, in favor of a resolution approving the compensation the Company pays to its "named executive officers" as d | 70,945,277 | 2,594,517 | 34,704 | -- | 11,211,890 | Majority: yes |
Source: Ultragenyx Pharmaceutical Inc., Form 8-K, filed with the SEC on 2026-05-18 — read the filing on EDGAR.
Each item below shows how the 318 asset managers that disclosed a Ultragenyx Pharmaceutical Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 6 wordings of this item as funds reported it.
96% Majority: yes · of votes cast
Ultragenyx Pharmaceutical Inc.’s own tally for this item (“Proposal 4: Advisory (Non-Binding) Vote to Approve Executive Compensation At the Annual Meeting, the Company's stockholders voted, on an advisory basis, in favor of a resolution approving the compensation the Company pay”): 70,945,277 for, 2,594,517 against, per its Form 8-K filed 2026-05-18 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 98,300,000 outstanding shares: 72% for, 3% against (75% of the company cast a for/against vote).
The 316 asset managers below cast 97% of the shares they voted on this item FOR (63,725,071 for, 1,769,100 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 11,477,641 | 8,226 | 0 | 0 | For |
| BlackRock | 6,486,089 | 0 | 0 | 0 | For |
| State Street | 4,780,105 | 8,499 | 0 | 0 | For |
| RTW INVESTMENTS, LP | 3,648,795 | 0 | 0 | 0 | For |
| Fidelity | 2,767,154 | 0 | 0 | 0 | For |
| SANDS CAPITAL MANAGEMENT, LLC | 2,150,083 | 0 | 0 | 0 | For |
| Wellington | 1,995,950 | 0 | 0 | 0 | For |
| AQR | 1,986,740 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,897,537 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 1,806,903 | 0 | 0 | 0 | For |
| GW&K Investment Management, LLC | 538,039 | 0 | 0 | 0 | Split |
| Rock Springs Capital Management LP | 1,199,769 | 0 | 0 | 0 | For |
| Sofinnova Investments, Inc. | 1,116,253 | 0 | 0 | 0 | For |
| Charles Schwab | 1,115,282 | 0 | 0 | 0 | For |
| Candriam S.C.A. | 1,096,182 | 0 | 0 | 0 | For |
| FRONTIER CAPITAL MANAGEMENT CO LLC | 1,026,607 | 0 | 0 | 0 | For |
| Two Sigma | 1,011,652 | 0 | 0 | 0 | For |
| DE Shaw | 1,005,994 | 0 | 0 | 0 | For |
| Citadel | 992,036 | 0 | 0 | 0 | For |
| John Hancock | 848,588 | 0 | 0 | 0 | For |
| Catalio Capital Management, LP | 825,624 | 0 | 0 | 0 | For |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 714,344 | 0 | 0 | 0 | For |
| TOUCHSTONE FUNDS GROUP TRUST | 660,316 | 0 | 0 | 0 | For |
| Nuveen | 654,599 | 0 | 0 | 0 | For |
| BNP Paribas Asset Management Holding S.A. | 0 | 639,441 | 0 | 0 | Against |
Showing the 25 largest of 316 asset managers. See all 316 in the interactive database.
Combines 2 wordings of this item as funds reported it.
69% Majority: yes · of votes cast
Ultragenyx Pharmaceutical Inc.’s own tally for this item (“Proposal 2: Approval of the Third A&R 2023 Plan At the Annual Meeting, the Company's stockholders approved the Third A&R 2023 Plan. The votes on Proposal 2 were as follows:”): 50,659,150 for, 22,888,600 against, per its Form 8-K filed 2026-05-18 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 98,300,000 outstanding shares: 51.5% for, 23% against (75% of the company cast a for/against vote).
The 85 asset managers below cast 86% of the shares they voted on this item FOR (22,063,488 for, 3,698,928 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 10,713,289 | 20,368 | 0 | 0 | For |
| State Street | 3,360,340 | 8,930 | 0 | 0 | For |
| BlackRock | 2,754,322 | 0 | 0 | 0 | For |
| Fidelity | 1,674,115 | 806,603 | 0 | 0 | For |
| T. Rowe Price | 728,282 | 0 | 0 | 0 | For |
| TOUCHSTONE FUNDS GROUP TRUST | 660,316 | 0 | 0 | 0 | For |
| TIAA | 0 | 622,850 | 0 | 0 | Against |
| AQR | 0 | 580,941 | 0 | 0 | Against |
| Charles Schwab | 557,616 | 0 | 0 | 0 | For |
| John Hancock | 6,718 | 403,330 | 0 | 0 | Against |
| AMG FUNDS | 0 | 288,538 | 0 | 0 | Against |
| MFS | 257,057 | 0 | 0 | 0 | For |
| Invesco | 221,501 | 0 | 0 | 0 | For |
| Nationwide | 0 | 113,788 | 0 | 0 | Against |
| FRANKLIN STRATEGIC SERIES | 108,067 | 0 | 0 | 0 | For |
| ALGER FUNDS | 0 | 107,143 | 0 | 0 | Against |
| Russell Investments | 96,646 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 94,362 | 0 | 0 | 0 | For |
| Goldman Sachs | 65,157 | 20,768 | 0 | 0 | For |
| Harbor ETF Trust | 83,656 | 0 | 0 | 0 | For |
| RBB FUND, INC. | 80,281 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 0 | 76,785 | 0 | 0 | Against |
| ProShares | 0 | 76,553 | 0 | 0 | Against |
| Delaware/Macquarie | 0 | 76,531 | 0 | 0 | Against |
| Bridge Builder Trust | 61,320 | 0 | 0 | 0 | For |
Showing the 25 largest of 85 asset managers. See all 85 in the interactive database.
Combines 4 wordings of this item as funds reported it.
90% Majority: yes · of votes cast
Ultragenyx Pharmaceutical Inc.’s own tally for this item (“Elect Director: Daniel G. Welch”): 66,301,426 for, 7,273,072 withheld, per its Form 8-K filed 2026-05-18 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 98,300,000 outstanding shares: 67% for, 7% withheld (75% of the company cast a for/withheld vote).
The 83 asset managers below cast 100% of the shares they voted on this item FOR (23,901,615 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 9,494,918 | 0 | 1,238,739 | 0 | For |
| State Street | 3,369,136 | 0 | 134 | 0 | For |
| BlackRock | 2,754,322 | 0 | 0 | 0 | For |
| Fidelity | 2,202,386 | 0 | 278,332 | 0 | For |
| T. Rowe Price | 728,282 | 0 | 0 | 0 | For |
| TOUCHSTONE FUNDS GROUP TRUST | 660,316 | 0 | 0 | 0 | For |
| TIAA | 622,850 | 0 | 0 | 0 | For |
| AQR | 580,941 | 0 | 0 | 0 | For |
| Charles Schwab | 557,616 | 0 | 0 | 0 | For |
| John Hancock | 410,048 | 0 | 0 | 0 | For |
| AMG FUNDS | 288,538 | 0 | 0 | 0 | For |
| MFS | 257,057 | 0 | 0 | 0 | For |
| Invesco | 221,501 | 0 | 0 | 0 | For |
| Nationwide | 113,788 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 108,067 | 0 | 0 | 0 | For |
| ALGER FUNDS | 107,143 | 0 | 0 | 0 | For |
| Russell Investments | 96,646 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 94,362 | 0 | 0 | 0 | For |
| Goldman Sachs | 82,250 | 0 | 3,675 | 0 | For |
| Harbor ETF Trust | 83,656 | 0 | 0 | 0 | For |
| RBB FUND, INC. | 80,281 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 76,785 | 0 | 0 | 0 | For |
| ProShares | 76,553 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 0 | 0 | 76,531 | 0 | Abstain |
| Bridge Builder Trust | 61,320 | 0 | 0 | 0 | For |
Showing the 25 largest of 83 asset managers. See all 83 in the interactive database.
Combines 4 wordings of this item as funds reported it.
99% Majority: yes · of votes cast
Ultragenyx Pharmaceutical Inc.’s own tally for this item (“Elect Director: Emil D. Kakkis, M.D., Ph.D.”): 72,517,613 for, 1,056,885 withheld, per its Form 8-K filed 2026-05-18 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 98,300,000 outstanding shares: 74% for, 1% withheld (75% of the company cast a for/withheld vote).
The 83 asset managers below cast 100% of the shares they voted on this item FOR (25,451,671 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 10,725,434 | 0 | 8,223 | 0 | For |
| State Street | 3,364,203 | 0 | 5,067 | 0 | For |
| BlackRock | 2,754,322 | 0 | 0 | 0 | For |
| Fidelity | 2,202,386 | 0 | 278,332 | 0 | For |
| T. Rowe Price | 728,282 | 0 | 0 | 0 | For |
| TOUCHSTONE FUNDS GROUP TRUST | 660,316 | 0 | 0 | 0 | For |
| TIAA | 622,850 | 0 | 0 | 0 | For |
| AQR | 580,941 | 0 | 0 | 0 | For |
| Charles Schwab | 557,616 | 0 | 0 | 0 | For |
| John Hancock | 410,048 | 0 | 0 | 0 | For |
| AMG FUNDS | 288,538 | 0 | 0 | 0 | For |
| MFS | 257,057 | 0 | 0 | 0 | For |
| Invesco | 221,501 | 0 | 0 | 0 | For |
| Nationwide | 113,788 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 108,067 | 0 | 0 | 0 | For |
| ALGER FUNDS | 107,143 | 0 | 0 | 0 | For |
| Russell Investments | 96,646 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 94,362 | 0 | 0 | 0 | For |
| Goldman Sachs | 85,925 | 0 | 0 | 0 | For |
| Harbor ETF Trust | 83,656 | 0 | 0 | 0 | For |
| RBB FUND, INC. | 80,281 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 76,785 | 0 | 0 | 0 | For |
| ProShares | 76,553 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 76,531 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 61,320 | 0 | 0 | 0 | For |
Showing the 25 largest of 83 asset managers. See all 83 in the interactive database.
Combines 4 wordings of this item as funds reported it.
89% Majority: yes · of votes cast
Ultragenyx Pharmaceutical Inc.’s own tally for this item (“Elect Director: Shehnaaz Suliman, M.D.”): 65,801,638 for, 7,772,860 withheld, per its Form 8-K filed 2026-05-18 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 98,300,000 outstanding shares: 67% for, 8% withheld (75% of the company cast a for/withheld vote).
The 83 asset managers below cast 100% of the shares they voted on this item FOR (22,056,043 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 10,720,702 | 0 | 12,955 | 0 | For |
| State Street | 6,331 | 0 | 3,362,939 | 0 | Abstain |
| BlackRock | 2,754,322 | 0 | 0 | 0 | For |
| Fidelity | 2,202,386 | 0 | 278,332 | 0 | For |
| T. Rowe Price | 728,282 | 0 | 0 | 0 | For |
| TOUCHSTONE FUNDS GROUP TRUST | 660,316 | 0 | 0 | 0 | For |
| TIAA | 622,850 | 0 | 0 | 0 | For |
| AQR | 580,941 | 0 | 0 | 0 | For |
| Charles Schwab | 557,616 | 0 | 0 | 0 | For |
| John Hancock | 410,048 | 0 | 0 | 0 | For |
| AMG FUNDS | 288,538 | 0 | 0 | 0 | For |
| MFS | 257,057 | 0 | 0 | 0 | For |
| Invesco | 221,501 | 0 | 0 | 0 | For |
| Nationwide | 113,788 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 108,067 | 0 | 0 | 0 | For |
| ALGER FUNDS | 107,143 | 0 | 0 | 0 | For |
| Russell Investments | 96,646 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 94,362 | 0 | 0 | 0 | For |
| Goldman Sachs | 85,925 | 0 | 0 | 0 | For |
| Harbor ETF Trust | 83,656 | 0 | 0 | 0 | For |
| RBB FUND, INC. | 80,281 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 76,785 | 0 | 0 | 0 | For |
| ProShares | 76,553 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 76,531 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 61,320 | 0 | 0 | 0 | For |
Showing the 25 largest of 83 asset managers. See all 83 in the interactive database.
Combines 2 wordings of this item as funds reported it.
99.7% Majority: yes · of votes cast
Ultragenyx Pharmaceutical Inc.’s own tally for this item (“Proposal 3: Ratification of Selection of Independent Registered Accounting Firm At the Annual Meeting, the Company's stockholders ratified the selection of Ernst & Young LLP as the independent registered public accountin”): 84,551,399 for, 221,802 against, per its Form 8-K filed 2026-05-18 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 98,300,000 outstanding shares: 86% for, 0.3% against (86% of the company cast a for/against vote).
The 83 asset managers below cast 99.9% of the shares they voted on this item FOR (25,761,069 for, 134 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 10,733,657 | 0 | 0 | 0 | For |
| State Street | 3,369,136 | 134 | 0 | 0 | For |
| BlackRock | 2,754,322 | 0 | 0 | 0 | For |
| Fidelity | 2,480,718 | 0 | 0 | 0 | For |
| T. Rowe Price | 728,282 | 0 | 0 | 0 | For |
| TOUCHSTONE FUNDS GROUP TRUST | 660,316 | 0 | 0 | 0 | For |
| TIAA | 622,850 | 0 | 0 | 0 | For |
| AQR | 580,941 | 0 | 0 | 0 | For |
| Charles Schwab | 557,616 | 0 | 0 | 0 | For |
| John Hancock | 410,048 | 0 | 0 | 0 | For |
| AMG FUNDS | 288,538 | 0 | 0 | 0 | For |
| MFS | 257,057 | 0 | 0 | 0 | For |
| Invesco | 221,501 | 0 | 0 | 0 | For |
| Nationwide | 113,788 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 108,067 | 0 | 0 | 0 | For |
| ALGER FUNDS | 107,143 | 0 | 0 | 0 | For |
| Russell Investments | 96,646 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 94,362 | 0 | 0 | 0 | For |
| Goldman Sachs | 85,925 | 0 | 0 | 0 | For |
| Harbor ETF Trust | 83,656 | 0 | 0 | 0 | For |
| RBB FUND, INC. | 80,281 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 76,785 | 0 | 0 | 0 | For |
| ProShares | 76,553 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 76,531 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 61,320 | 0 | 0 | 0 | For |
Showing the 25 largest of 83 asset managers. See all 83 in the interactive database.
Ranked by the number of Ultragenyx Pharmaceutical Inc. shares each manager voted on the most widely held ballot item of the 2025-2026 meeting, shown as a share of the 98,300,000 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 11.68% |
| 2 | BlackRock | 6.60% |
| 3 | State Street | 4.87% |
| 4 | RTW INVESTMENTS, LP | 3.71% |
| 5 | Fidelity | 2.82% |
| 6 | SANDS CAPITAL MANAGEMENT, LLC | 2.19% |
| 7 | Wellington | 2.03% |
| 8 | AQR | 2.02% |
| 9 | T. Rowe Price | 1.93% |
| 10 | GEODE CAPITAL MANAGEMENT, LLC | 1.84% |
Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).
| Holder | % outstanding | Disclosure |
|---|---|---|
| RTW Investments, LP | 7.93% | 13G |
| BlackRock | 7.43% | 13F |
| Vanguard Portfolio Management | 6.97% | 13G |
| State Street | 5.11% | 13F |
| AQR Capital | 4.66% | 13F |
| FMR LLC | 3.41% | 13G |
| Wellington Management | 2.69% | 13F |
| Citadel Advisors | 2.41% | 13F |
| Two Sigma | 2.24% | 13F |
| Morgan Stanley | 1.86% | 13F |
Percentages above are of 98,300,000 shares outstanding, as reported by Ultragenyx Pharmaceutical Inc. on its Form 10-Q dated 2026-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Ultragenyx Pharmaceutical Inc.’s 10-Q dated 2026-03-31. This page is a static snapshot rebuilt weekly on 04 October 2026; a live search always shows the current data.
At Ultragenyx Pharmaceutical Inc.'s shareholder meeting held 2026-05-14, in the 2025-2026 proxy season, 318 asset managers reported how they voted on 6 ballot items in their SEC Form N-PX filings, covering 1,942 separate fund positions. On the most widely held item on that ballot — Advisory (non-binding) vote to approve the compensation of our named executive officers. — FOR was 96% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Ultragenyx Pharmaceutical Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2026-05-18.
Ultragenyx Pharmaceutical Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).